Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Patient scheduled to undergo elective total knee replacement or revision of a primary procedure performed ≥ 6 months prior to study entry.~Exclusion Criteria:~* Any major orthopedic surgery in the 3 months prior to study entry;~* Clinical signs or symptoms of DVT or PE within the last 12 months or known post-phlebitic syndrome;~* Known sensitivity to iodine or contrast dyes;~* Recent stroke or myocardial infarction;~* High risk of bleeding;~* Treatment with other anti-thrombotic agents within 7 days prior to surgery;~* Any contra-indication to Unfractionated Heparin or Low Molecular Weight Heparin;~* Pregnant or nursing woman, or woman of childbearing potential who is not using an effective contraceptive method.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semuloparin 5 mg (Type: EXPERIMENTAL): Semuloparin sodium 5 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
- Semuloparin 10 mg (Type: EXPERIMENTAL): Semuloparin sodium 10 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
- Semuloparin 20 mg (Type: EXPERIMENTAL): Semuloparin sodium 20 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
- Semuloparin 40 mg (Type: EXPERIMENTAL): Semuloparin sodium 40 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
- Semuloparin 60 mg (Type: EXPERIMENTAL): Semuloparin sodium 60 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
- Enoxaparin 40 mg (Type: ACTIVE_COMPARATOR): Enoxaparin sodium 40 mg + Placebo (for Semuloparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
- Placebo pre-op / Semuloparin 20 mg (Type: EXPERIMENTAL): Placebo (for Semuloparin sodium) + Placebo (for Enoxaparin sodium) 12 hours before surgery then,~Semuloparin sodium 20 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 8 hours after surgery
- Placebo pre-op / Semuloparin 40 mg (Type: EXPERIMENTAL): Placebo (for Semuloparin sodium) + Placebo (for Enoxaparin sodium) 12 hours before surgery then,~Semuloparin sodium 40 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 8 hours after surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).